Abstract
Small-interfering RNA (siRNA) shows great promise as a therapy to silence disease-causing genes. Clinical gene therapy of RNA (siRNA) for cancer treatment is investigated. Advances in the delivery systems of RNA therapeutics from concept to clinical reality are studied. MicroRNAs are endogenous regulators of gene expression that are deregulated in several cellular diseases including cancer. For the therapeutic application of siRNA there are technical challenges with respect to targeted and systemic delivery. The study has reported a new siRNA carrier comprising RNAtr (transcript) NPs, in which multiple tandem copies of RNA hairpins can be readily adapted in tumor-targeted and systemic siRNA delivery as a result of rolling circle transcription (RCT). Two types of small RNA molecules—siRNAs and microRNAs (miRNAs)—have a central function in RNAi technology. Despite the advances in anticancer therapy its effectiveness for many human tumors is still far from being optimal. The clinical success of therapeutics using siRNA is still hindered by its delivery systems.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
